chrisvoncsefalvay/vaers-outcomes huggingface dataset:
VARlVAX and MMRII administered with 0.9 sodium chloride instead of the supplied sterile diluent; No additional AE; This spontaneous report was received from a registered Nurse referring to a currently 1 year old patient. The patient's medical history, concurrent conditions, drug/allergy history and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, 0.5 milliliter, lot #T016195, expiration date: 11-JUN-2022, administered for prophylaxis (strength, and route of administration were not provided); varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, 0.5 milliliter, lot #T032316, expiration date: 22-SEP-2022, administered for prophylaxis (strength, and route of administration were not provided). The reporter stated that vaccines were administered with sodium chloride 0.9 lot #27-065-DK, expiration date: 01-MAR-2023 (strength, formulation, route of administration, and indication were not provided), instead of the supplied diluent (Product preparation issue). No additional adverse event was reported.
Information was received on 28-AUG-2017 from a Licensed Practical Nurse who was reporting on an unspecified number of patients. No medical history or concomitant medications were provided. The nurse reported that on unspecified dates, an unspecified number of patients were administered improperly stored PEDVAXHIB (lot N003700, expires 01-NOV-2019; lot M014926, expires 17-FEB-2019), RECOMBIVAX (lot M008551, expires 02-JUN-2018; lot M046373, expires 04-NOV-2019) and PNEUMOVAX 23 (lot M040804, expires 20-MAY-2018) vaccines. The temperature was between 32 degrees F and 35 degrees F (32.4 degrees F) for 14 hour and 30 minutes. There was a previous temperature excursion between 32 degrees F and 35 degrees F (34.9 degrees F) for 30 minutes. This was not due to a data logger. No adverse effects were reported. No further information was reported. Additional information has been requested.
THE PATIENT'S LEFT ARM WAS VERY SWOLLEN WHICH STARTED AT THE DELTOID AND EXTENDED DOWN TO HIS ELBOW. HE WAS SEEN IN TO THE CLINIC AND DIAGNOSED WITH A CELLULITIS. HE WAS GIVEN INJECTIONS OF ROCEPHIN AND THEN GIVEN AN ORAL ANTIBIOTIC.
had difficulty breathing; Raised area at injection site; Redness at injection site; Pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (had difficulty breathing), VACCINATION SITE SWELLING (Raised area at injection site), VACCINATION SITE PRURITUS (Redness at injection site) and VACCINATION SITE PAIN (Pain at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced DYSPNOEA (had difficulty breathing), VACCINATION SITE SWELLING (Raised area at injection site), VACCINATION SITE PRURITUS (Redness at injection site) and VACCINATION SITE PAIN (Pain at injection site). At the time of the report, DYSPNOEA (had difficulty breathing), VACCINATION SITE SWELLING (Raised area at injection site), VACCINATION SITE PRURITUS (Redness at injection site) and VACCINATION SITE PAIN (Pain at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included unknown.   Reporter did not allow further contact
pt recvd vax & devel hematoma at the deltoid where inject was given; pt tx w/ ice & compression w/1st vax; pt showed lack of pos titer w/2nd & 3rd vax;
pt w/ diffuse s/s including muscles tremors, twitching, unable to concentrate, memory loss, fatigue;
Felt dizzy and nauseous at about 7:30pm following a workout 3 hours after I got the Pfizer vaccine. Dizziness has increased and I feel fatigued.
Wife states that her husband (patient) went into congestive heart failure and died a few days after receiving the flu vaccine.
a Acute MI of the LAD; pulmonary embolism that resulted in sudden death; sudden death; symptoms of fatigue; fever; congestion; This is a spontaneous report from a contactable consumer (patient's wife) reported for her husband (the patient). A 62-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 27Sep2021 10:00 (Lot Number: 301358A) at the age of 62-year-old as single dose for covid-19 immunization at a Pharmacy or Drug Store. Medical history included COVID prior vaccination, Asthma, Atrial fibrillation (A-fib), Hyperlipidemia, bradycardia, Obstructive Sleep Apnea, Mild mitral and tricuspid regurgitation. No known allergies. Concomitant medications included apixaban (ELIQUIS); atorvastatin calcium (LIPITOR); digoxin; flecainide; and tadalafil (CIALIS); all taken for unspecified indications, start and stop dates were not reported. No other vaccine in four weeks. Historical vaccine included bnt162b2, dose 1 on 06Sep2021 11:00 (Lot Number: 301308A) at the age of 62-year-old for covid-19 immunization. The reporter's husband had a Acute MI (myocardial infarction) of the LAD (left anterior descending) on 03Oct2021, six days after second Covid-19 and pulmonary embolism that resulted in sudden death. He experienced symptoms of fatigue, fever, congestion after both vaccines. The above mentioned events were reported as started from On 03Oct2021 17:30, and resulted in patient died. No treatment for the above mentioned events. The patient died on 03Oct2021. Also reported death causes as Acute MI and pulmonary embolism. An autopsy was performed that remarked "Acute MI to LAD". No COVID tested post vaccination.; Reported Cause(s) of Death: congestion; fever; sudden death; symptoms of fatigue; pulmonary embolism; a Acute MI of the LAD; Autopsy-determined Cause(s) of Death: Acute MI to LAD
Information has been received from a registered nurse concerning a patient with milk allergy and egg allergy who at age 15-18 months of age was vaccinated with a dose of MMR II. Subsequently the patient showed symptoms of autism. It was unknown if the patient sought any medical attention. At the time of this report, the now 36 month old patient had not recovered. Upon internal review, autism was determined to be an other important medical event. This is one of several reports from the same source. Additional information has been requested.
Pain inside the armpit (not able to locate it by touching the area); This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 28Apr2021 at 17:30 as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Concomitant medications included multivitamins (MANUFACTURER UNKNOWN), vitamin d nos (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C) and zinc (MANUFACTURER UNKNOWN); all taken from unknown date for unspecified indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 07Apr2021 at 17:45 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 29Apr2021 at 20:00 the patient experienced pain inside the armpit (not able to locate it by touching the area). The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.  No therapeutic measures were taken as a result of the event. The clinical outcome of the event pain inside the armpit (not able to locate it by touching the area) was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Began having sore arm almost immediately. About 12 hour after injection, began having hives without respiratory symptoms. Responding to oral antihistamines. But hives continue today (2-25-13).
Dizziness Narrative:  Employee had waited her 15 minutes and left the room. Came back to room and stated she felt dizzy. Vital signs taken and stable. Pt taken to ER for further evaluation.
Patient presented to the ED in cardiac arrest following morning after receiving 2 month vaccines previous afternoon.   Per mom she last saw the child 3 hours prior to recognizing the patient to be pulseless.  The baby sleeps in bassinet with their twin sibling.  Patient mother states that she fed the child 3 hours previous and child appeared in no distress.   On medic arrival patient was pulseless IO established.   Patient found to be hypoglycemic and given D10 8 mL.  Patient received three epi prior to hospital arrival.  Protocol was pursued.  Patient remained pulseless and asystolic the entire time. 43 minutes of CPR performed until time of death.
Pt recvd Td booster & did well; immed p/vax exp sz type activity, eyes rolled back, sitffness, unresponsive; lasted 20-30 sec; BP 90/54; pt pale, & was unable to recall what happen, hyperventilate, P46, spotty red rash;
This spontaneous report as received from a nurse refers to her daughter. The nurse reported that her daughter received all 3 doses of GARDASIL, however, nurse found out that second dose of GARDASIL her daughter received in early April 2014 was improperly stored due to temperature excursion. Nurse received a call from daughter's physician's (name unspecified) office informing her that second dose of GARDASIL given to her daughter underwent temperature excursion (details not provided) and physician wanted to revaccinate her daughter. No adverse effects reported. Additional information has been requested.
DEVELOPED VARICELLA LESIONS 4 DAYS AFTER RECEIVING VARIVAX
STARTED HAVING SEIZURES-ATONIC & MYOCLONIC (LOSING MUSCLE TONE IN THE UPPER BODY) AFTER GIVEN HIS 6 MONTHS VACCINES & 1ST FLU SHOT. WAS HAVING THEM 20+/DAY. HAS SINCE HAD SEVERAL DR VISITS, EEG, MRI. IS ON ZONOGRAN TO CONTROL THEM. NO OTHER KNOWN CAUSE.
Chills beginning around three pm that got progressively worse, a fever starting around eight pm and very heavy feeling arms, feeling of intense dizziness / unable to walk. Fever has started breaking by 9:30  but dizziness is still present as his heavy feeling in arms though I can use them more now.
Patient was vaccinated on 3/1/2021 with 1st dose Pfizer, lot EN6205 expiration date 6/30/2021. Patient informed RN  that he had flushing, felt hot and dizzy approximately 2min after receiving 1st dose and symptoms resolved 2min afterwards. Patient denied allergies, medications, and medical conditions. Patient suffers from seasonal allergies. RN relayed information to PHN  who texted the medical team. Per the medical team, patient is to wait until 28 days post 1st Pfizer dose before receiving Janssen vaccine, it is not recommended to receive Pfizer 2nd dose. Patient was advised to consult with his provider. VAERS report submitted 3/24/2021, confirmation number
Pt experienced swelling and redness in shoulder with pain at times. Pt is able to move arm but difficulty making a fist. No strength.
pt recv vax;lips&hands were blue;was shaking;purple around the mouth;somewhat fussy but has been drinking and urinating nl;T 104.3;P 152;
So on Aug. 4th, I lost my voice and it had been gone for almost two days, I decided to COVID test and it was positive. The following day, I had a severe headache that lasted about six hours. I had severe fatigue for about three days, and I never had very bad pulmonary symptoms. I did experience brain fog and difficulty word finding. Three weeks after the initial infection I began having burning sensation on my arm. As of March 2, 2022, the brain fog and burning sensation has not subsided.
patient called this morning around 9:00 am. She states that since getting her covid vaccination yesterday, she feels really sick. Fever/achy and she is having facial swelling. She said she didn't feel like this after the first dose. Since facial swelling is an abnormal and dangerous side effect, I recommended she go to the ER (or at least an urgent care) to be evaluated immediately because she doesnt want the facial swelling to get worse or extend to her breathing. She stated at that time she was having no trouble with her throat or breathing. She said she was going to go to the ER. I told her in the meantime she could take liquid benadryl while on her way to  the ER
EUA Pfizer-BioNtech vaccine patient presented to ER the next day following covid-19 immunization with angioedema. She experienced tongue swelling. Her airway is open and and patent and and she denies other allergic symptoms such as rash or pruritis
unconsolable crying (high-pitched screams 1hr @ a time);x 2 days;fever
The expired Jynneos vaccine was administered to the patient, intradermally; The expired Jynneos vaccine was administered to the patient, intradermally; Case reference number US-BN-2023-000053 is a spontaneous case report initially received from other health care professional via Communications (reference number: USBAV23-0059) on 11-Jan-2023 and concerns an adult patient of unknown gender.  The patient's medical history and concomitant medication details were not provided.  On 03-Jan-2023, the patient was vaccinated with the first dose of expired Jynneos vaccine (batch number: FDP00014; expiration date: 19-Dec-2022), at an unknown dose or site of administration, intradermally, for monkeypox (explicitly coded as 'expired vaccine used' and 'intradermal injection').    At the time of this report, it was unknown if the patient experienced any adverse event due to Jynneos.  Additional information received from Bavarian Nordic on 11-Jan-2023 included the local BN case ID.  This case is linked to cases US-BN-2023-000050, US-BN-2023-000051, US-BN-2023-000052, US-BN-2023-000054 and US-BN-2023-000055 (same reporter).; Reporter's Comments: An adult patient of unknown gender born in 1968 was vaccinated with the first dose of expired Jynneos vaccine, at an unknown dose or site of administration, intradermally, for monkeypox, which is considered as expired product administered. No associated adverse events were reported. Intradermal injection and expired product administered are listed per company convention. The patient's medical history and concomitant medication details were not provided. Intradermal injection and expired product administered are not related to Jynneos vaccine, but to a human factor. The case is non-serious.; Sender's Comments: An adult patient of unknown gender was vaccinated with the first dose of expired Jynneos vaccine, at an unknown dose or site of administration, intradermally, for monkeypox, which is considered as expired product administered. No associated adverse events were reported. Intradermal injection and expired product administered are listed per company convention. The patient's medical history and concomitant medication details were not provided. Intradermal injection and expired product administered are not related to Jynneos vaccine, but to a human factor. The case is non-serious.
Ph call from client who states she received MMR and Tdap on 3/5/10. 1 wk after receiving the vaccines her chin and glands on side of her neck became swollen. A fine rash appeared on face & arms 3-4 days ago. Symptoms are still present. No treatment yet.
Onset of constant ringing or tinnitus in both ears,  within one day after my first shot.  It continues to this day, nearly 9 months later.
I felt like I had the flu for the last 6 weeks, severe coughing, trouble breathing, body aches, muscle weakness, fogginess, no energy, headaches
Due to Anthrax vaccine, patient has been experiencing severe allergic reactions, without brakes that occur two times a day everyday.
Follow-up info received from the pt's physician provided the following: adverse event info including symptoms, onset, and recovery status; pt's gender and date of birth; concomitant medications; illnesses at the time of vaccination; and medical history. A health care professional reported that a 9 year old male pt received a dose of Flumist on an unspecified date in Oct 2003, and experienced flu-like symptoms, sore throat, ear congestion, runny nose, cough, nausea, vomiting, and loose stools. Within 24 hrs of vaccination, the pt experienced flu-like symptoms, sore throat, ear congestion, runny nose, cough, nausea, vomiting and loose stools. The symptoms lasted more than five days. The pt has recovered.
Systemic: Confusion-Medium, Systemic: Fainting / Unresponsive-Medium, Systemic: Numbness (specify: facial area, extremities)-Medium, Systemic: Tingling (specify: facial area, extemities)-Medium, Systemic: Visual Changes/Disturbances-Medium, Additional Details: TINGLING IN FEET
client had syncope episode after receiving 1st dose Pfizer Covid Vaccine. Client received vaccine at 1336 and was standing next to vaccine station and Father as sibling was receiving vaccine. Within 3 minutes of standing client had syncope episode and hit back of head on floor. RNs responded. PHN called 911 at 1340. Per RN client collapsed and hit back of head, Father tried to hold on but was unsuccessful. As PHN was speaking with paramedics, client regained consciousness. Client stated she remembered feeling dizzy and then woke up on the floor. Client alert and oriented, pale and stated blurry vision. RN elevated legs. Vitals: blood pressure 130/90, pulse 102, oxygen 99%. Father denied any relevant medical history, medications, allergies or history of syncope. Client stated feeling dizzy, denied pain on head or rest of body. Paramedics arrived approximately 1346 and assumed care. After assessment Father signed AMA with paramedics. Client sat in anti gravity chair after paramedics left. EMT stayed with client. Vitals at 1412: blood pressure 120/80, pulse 85, oxygen 96%. Client stated feeling dizzy and head hurts when she moves. Blurry vision resolved. PHN spoke with parents to review ER precautions and advised to make follow up appointment with primary doctor. After sibling was done with observation, client left facility at 1425 with steady gait.
pt recvd Engerix-B vax & was non responder p/3 doses; 24JAN92 neg titer;
Menveo reconstituted at 11 am on 31 oct 2023 and admintered at 8 am next day; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong technique in drug usage process in a 12-year-old female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On 01-NOV-2023, the patient received Menveo. On 01-NOV-2023, an unknown time after receiving Menveo, the patient experienced wrong technique in drug usage process (Verbatim: Menveo reconstituted at 11 am on 31 oct 2023 and admintered at 8 am next day). The outcome of the wrong technique in drug usage process was unknown.   Additional Information: GSK receipt date: 01-NOV-2023 The health care professional reported that administration of Menveo (2-vial) that was reconstituted one day before the reporting date at 11 am and on the day of reporting, administered at 8 am, which led to wrong technique in drug usage process. The reporter consented to follow up.
Patient experienced skin itching post-Pfizer #1. She indicated she is allergic to latex and Benadryl, and had a previous reaction to the pneumococcal vaccine. Itching did not progress to hives at the vaccine site. Her blood pressure was elevated (she has hx of HTN):  22/113; 225/116; 219/114 (over 30 minutes); HR 80, RR 18 per EMS report. No PSO2 assessed. She declined EMS transport. She was counseled by a health department RN to discuss the reaction with her doctor prior to receiving the second vaccine.
vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were provided. Patient did not experience any other adverse reactions.   This case was linked to MOD-2021-395985 (Patient Link).
Pt given 4 injectable vaccines and oral typhoid capsules on 9/18/06. He took first oral typhoid capsule on 10/2, second capsule on 10/4 and called office on 10/5/06 with complaint of irregular heart rhythm, pressure in chest, stiff neck, muscle aches. He went to local hospital ER for evaluation. States he was told by ER physician he had no cardiac problems and that could be reaction to oral thyroid vaccine.
Maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     Concurrent medical conditions included Anxiety depression. Concomitant products included PRENATAL MULTIVITAMIN + DHA for Pregnancy, ZOLOFT for an unknown indication.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was in August 2020 and the estimated date of delivery was 10-May-2021. On 01-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY. The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  ninth month of the pregnancy.  On 01-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications also included Iron supplement. No treatment information was provided. Previous pregnancy end date was on 28 Apr 2021 resulted into live birth.   Most recent FOLLOW-UP information incorporated above includes: On 11-Feb-2021: Follow up received and added concomitant medications.